Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 6/20 | 0.35 |
| ▸ | HTR2C | P28335 | 6/20 | 0.35 |
| ▸ | HTR1A | P08908 | 5/20 | 0.35 |
| ▸ | HTR2B | P41595 | 5/20 | 0.35 |
| ▸ | HTR1D | P28221 | 4/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.31 |
| ▸ | WNT3A | P56704 | 1/20 | 0.31 |
| ▸ | FABP6 | P51161 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | LOX | P28300 | 1/20 | 0.30 |
| ▸ | HTR6 | P50406 | 2/20 | 0.30 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.30 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.30 |
| ▸ | HTR1B | P28222 | 1/20 | 0.30 |
| ▸ | HTR7 | P34969 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29809660 | 1.00 | HTR2A (0.35) | HTR2AHTR2CHTR1AHTR2BHTR1D | |
| SCHEMBL18106619 | 0.88 | PARP1 (0.37) | NPC1PARP1FABP6MAOAMAOB | |
| SCHEMBL7831214 | 0.82 | P2RX7 (0.31) | HTR2AHTR2CHTR1AHTR2BHTR1D | |
| SCHEMBL31204901 | 0.81 | LMNA (0.35) | HTR2AHTR2CHTR1AHTR2BHTR1D | |
| SCHEMBL12169271 | 0.77 | HTR2C (0.35) | HTR2AHTR2CHTR1AHTR2BHTR1D | |
| SCHEMBL28509258 | 0.76 | SMN1; SMN2 (0.34) | — | |
| SCHEMBL1895331 | 0.74 | FABP6 (0.37) | PARP1FABP6HTR6 | |
| SCHEMBL16309083 | 0.73 | L3MBTL1 (0.46) | HTR1A | |
| SCHEMBL4344995 | 0.72 | PARP1 (0.46) | HTR1APARP1CTNNB1WNT3A | |
| SCHEMBL24457968 | 0.72 | EED (0.33) | PARP1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116904533-A | Preparation method of (R) -5, 7-difluoro-3, 4-dihydro-2H-1-benzopyran-4-ol | 浙江理工大学 | 2023-10-20 | — | — | CN | claimed |
| CN-121574952-A | Carbonyl reductase mutant and application thereof in preparation of chiral alcohol | 江西师范大学 | 2026-02-27 | — | — | CN | disclosed |
| US-12466803-B2 | BCKDK inhibitors and/or degraders | PFIZER INC. (US) | 2025-11-11 | — | — | US | disclosed |
| CN-118451066-A | 3-Phenyl-1-benzothiophene-2-carboxylic acid derivatives as inhibitors of branched alpha ketoacid dehydrogenase kinase for the treatment of diabetes, kidney disease, NASH and heart failure | 辉瑞大药厂 | 2024-08-06 | — | — | CN | disclosed |
| CN-116904533-A | Preparation method of (R) -5, 7-difluoro-3, 4-dihydro-2H-1-benzopyran-4-ol | 浙江理工大学 | 2023-10-20 | — | — | CN | disclosed |
| WO-2023100061-A1 | 3-PHENYL-1-BENZOTHIOPHENE-2-CARBOXYLIC ACID DERIVATIVES AS BRANCHED-CHAIN ALPHA KETO ACID DEHYDROGENASE KINASE INHIBITORS FOR THE TREATMENT OF DIABETES, KIDNEY DISEASES, NASH AND HEART FAILURE | PFIZER INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| US-20230167080-A1 | BCKDK INHIBITORS AND/OR DEGRADERS | PFIZER INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230167080-A1 | BCKDK INHIBITORS AND/OR DEGRADERS | PFIZER INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230167080-A1 | BCKDK INHIBITORS AND/OR DEGRADERS | PFIZER INC. (US) | 2023-06-01 | — | — | US | disclosed |
| WO-2022144785-A1 | PHARMACEUTICAL COMPOSITION COMPRISING TEGOPRAZAN AND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | HK INNO.N CORPORATION (KR) | 2022-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12466803-B2 | BCKDK inhibitors and/or degraders | BCKDK, KHK, PDK4 | HTR2A 4437/4885HTR2C 4301/4885HTR1A 4538/4885 |
| US-20230167080-A1 | BCKDK INHIBITORS AND/OR DEGRADERS | BCKDK, KHK, PDK4 | HTR2A 4437/4885HTR2C 4301/4885HTR1A 4538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.